This Obesity Drug Stock Surges 60% on Phase 3 News
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Understanding which risk dominates can guide your allocation decisions. This comparison highlights when inflation worry or market dips matter more.
28,524 articlesA notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
A surprising all-stock deal sent ON Semiconductor lower, wiping out gains from a strong AI data center narrative. Her...
When a biotech deal moves a small cap, it can set the tone for the whole sector. This story explains what happened wi...
Small modular reactors could redefine electricity costs and energy security. This guide breaks down the investment th...
Cathie Wood's bold bets launched a new era for ETFs. This piece explains how ARK helped fuel demand for active ETFs, ...
AST SpaceMobile has captured attention with a surge tied to high-profile deals. This guide breaks down what the stock...
Upstart is pivoting beyond personal loans into new lending frontiers. This in-depth guide breaks down the big move, h...
VCR is down about 9% year-to-date, but nearly 40% of its holdings sit in Amazon and Tesla, reshaping the fund’s risk ...
SoundHound AI is chasing a $140 billion total addressable market. This article breaks down what that TAM means for in...
As Elon Musk crosses a trillion dollars in net worth, the real question for Tesla investors shifts from hype to strat...
June data show a slower payroll rise and a drop in participation, fueling debate over the Fed’s 2026 path. The result...
Looking for biotech growth with real upside? This piece breaks down two innovative biotech stocks that could deliver ...